Open in interactive viewer → charts, metric popovers & call review

Lumexa's Raise Came From the Tax Line; Its Future Came From a Fee Schedule

Q3 delivered genuine cash-flow momentum and a $44B bigger sandbox — but the EPS upgrade was arithmetic, and the stock fell 31% in four days on the way into the print.
LMRI · Earnings Call · 2026-11-10

The raise that wasn't an operating raise

Lumexa Imaging reported Q3 2026 with consolidated revenue of $272 million, up 5%, adjusted EBITDA of $62.6 million versus $59.1 million a year ago, and a 23.0% adjusted EBITDA margin that ticked up from 22.8% — the first year-over-year margin expansion since the company went public. That last detail matters more than it looks: Tony Martin, the CFO, had spent two prior calls explaining why the first half of 2026 would look flat while the back half carried the year. The 45/55 first-half/second-half split he first laid out in August landed almost exactly. Then came the guidance section, which is where the quarter gets interesting in a way the headline does not.

We are again narrowing our adjusted EBITDA guidance range. This time, to $236 million to $240 million. Versus the previous range of $235 million to $241 million. While maintaining the midpoint.

J. Anthony Martin, Chief Financial Officer · 2026-11-10
Narrowing a $6 million range to a $4 million range while holding the $238 million midpoint is not a raise; it is housekeeping. Consolidated revenue guidance was reiterated outright at $1.045 billion to $1.097 billion. The one number that moved materially was adjusted EPS — to $0.86 to $0.90 from $0.71 to $0.77, a roughly 20% lift at the midpoint — and Martin was admirably plain about why: “This increase is driven primarily by a lowered assumed effective tax rate for the year. With no change to our underlying operating assumptions.” — J. Anthony Martin, Chief Financial Officer · 2026-11-10 So the quarter's most quotable upgrade is a tax-rate assumption, and management says so out loud. That is not a red flag by itself — it is honest disclosure — but it is the single most important thing to hold onto when the stock's reaction is being read. The business did improve; the guidance barely did.

From FastScan to fee schedules: the narrative rotated

The company's own keyword record shows an unusually clean rotation. Through the first three quarters of 2026, the top of the Lumexa stack was operational and technological: Lumexa Connect, Virtual MRI, FastScan, PET machines, the Technologist Advancement Academy, referring physicians, strategic service lines. In this quarter's top-30, the technology vocabulary is largely gone and the policy vocabulary has taken its place — hospital outpatient, site neutrality, addressable market, Medicare reimbursement, and conversion factor all enter fresh. FastScan, which spiked into the top-30 as recently as last quarter, is the single largest keyword decliner in the current snapshot. That is not because the technology stopped working — Caitlin Zulla noted it is now deployed across the majority of the enterprise, shortening MRI acquisition by up to 40% — but because it has become plumbing rather than a growth story. What replaced it is the finalization of CMS's 2027 hospital outpatient rule on site-neutrality. Zulla's framing is that this takes Lumexa's addressable market from roughly $33 billion in independent diagnostic testing facilities to about $77 billion, by adding a $44 billion hospital-outpatient imaging pool. That is the biggest new number in the release, and it is worth noting it is a market-sizing number, not a revenue number. The discipline of the language is the tell. This is the same claim the company made in August, when the rule was only proposed:

I see this as a multiyear catalyst versus something that's going to change our results immediately. What I do think it does is it reinforces the conversations that are already happening.

Caitlin Zulla, Chief Executive Officer · 2026-08-12
And in November, with the rule finalized, the tone barely moved: “We see the movement towards site-neutral reimbursement as a tailwind that would unfold over years, not quarters.” — Caitlin Zulla, Chief Executive Officer · 2026-11-10 That consistency is credible — management is not pretending a policy change will show up in Q1 2027 revenue. But it also means the near-term case still rests on the same levers as before: De Novos (five opened year-to-date, an 8-to-10 target, three opened in early November across Texas, South Carolina and North Carolina), advanced modality mix at a record 38.2% of system-wide volume, and PET growth of 19.5%. One genuine corroboration: the global tape's top 30-day advancer is the de novo facility cluster — RadNet, Acadia and Surgery Partners — up over 30% in a month. Lumexa's growth architecture is riding a wave the market is already paying for elsewhere in the outpatient complex.

What the cash flow says that the guidance doesn't

The strongest part of the quarter is buried below the EBITDA line. Cash from operations was $34.8 million, $23 million better than a year ago, and free cash flow swung to positive $20.6 million from negative $1.8 million — roughly 33% conversion of adjusted EBITDA. Management had guided 25% to 30% in August; it now guides to at least 30% for the full year. That is a real, unhedged upgrade, and it came with $14.2 million of capital spending in the quarter and a deliberate decision to lean into more CapEx in the fourth quarter. Balance sheet progress is equally concrete: cash of $90 million versus $69.7 million at the start of the quarter, and net leverage of 3.5x against 5.6x a year ago, helped by a term-loan repricing in June that cut the spread by 50 basis points and an interest expense line that fell about $14 million year over year to $15.7 million. Two accounting textures are worth flagging because they distort the optics. First, the management fee line: of $60.9 million, only about $26 million is core management fee from the joint ventures — the other $35 million is zero-margin pass-through of employee, IT and site costs. Second, stock-based compensation ran $12.3 million versus $8.3 million, and roughly half of the full-year $50 million relates to historic M&A and burns off by year-end, with ongoing SBC of $20 million to $28 million guided for 2027. Both mean the reported top line and expense base overstate the underlying economics in ways investors have been slow to model.

The tape is the warning label

For all the operational progress, Lumexa's stock has been a violent instrument. It came public at $18.53 in December 2025, fell 58% over 22 weeks, then rallied 117% in 15 weeks — and then dropped 31% in the last four trading days into this report. A name up 127% over sixteen weeks that sheds nearly a third of its value in four sessions is a name where positioning, not fundamentals, is setting the price. The market had already decided site-neutrality was a story; the question the print had to answer was whether earnings would follow, and the answer was: revenue flat to guidance, EBITDA midpoint unmoved, EPS higher on tax. That is why the reimbursement fine print deserves scrutiny. Medicare fee-for-service plus Medicare Advantage is about 20% of revenue, and Zulla's initial read is a roughly negative 1% Medicare rate for 2027 — “The initial analysis is modestly below 0 for Medicare. So think about it approximately negative 1%.” — Caitlin Zulla, Chief Executive Officer · 2026-11-10 Some of that is the expiration of a temporary 2.5% conversion-factor bump that Congress has restored before; management openly flags potential legislative relief. Commercial contracts, the majority of the book, are nearly fully negotiated for 2027. The recurring worry — payer mix — remains a non-event, and was described that way both this quarter and in August: “There was a very slight downward tick but nothing significant” — J. Martin, Chief Financial Officer · 2026-08-12. Labor is the same story with the same number attached, repeated almost verbatim across two quarters: “We continue to see operating expenses increasing at about 5% a year, which is right where it is been” — J. Anthony Martin, Chief Financial Officer · 2026-11-10, echoing the prior call's “Our operating expenses from '25 to '26” — J. Martin, Chief Financial Officer · 2026-08-12 up 5%. Where does that leave the story? Lumexa is a $1.5 billion outpatient imaging consolidator that just proved it can convert EBITDA into cash and delever while growing, and that just had its addressable market handed a policy tailwind measured in tens of billions. It also just told investors, in plain language, that the tax rate — not the business — did the upgrading this quarter, that the site-neutrality windfall arrives over years, and that formal 2027 guidance waits until March. The Dr. Pirooz hire as Chief Clinical AI Officer and the advancing Medicare reimbursement math are real threads, but neither is a 2027 earnings lever yet. For a stock that rallied 127% and then fell 31% in four sessions, the honest read is that the equity has already priced the fee schedule. What it has not yet been shown is the revenue line that proves it.